NPM1 and CEBPA Test Cost AED 2700.0 | Symptoms, Diagnosis, and More
At DNA Labs UAE, we offer the NPM1 and CEBPA test, which is a genetics test commonly associated with acute myeloid leukemia (AML). This test helps in the diagnosis and treatment planning for AML patients. Here are the details of the test:
Test Name: NPM1 and CEBPA Test
- Components: EDTA Vacutainer (2ml)
- Price: 2700.0 AED
- Sample Condition: Bone marrow / Peripheral blood (Transport immediately)
- Report Delivery: 7-8 days
- Method: Sanger Sequencing
- Test Type: Genetics
- Doctor: Gynecologist
- Test Department: Pre Test Information
Please note that the NPM1 and CEBPA test requires a doctor’s prescription. However, it is not applicable for surgery and pregnancy cases or people planning to travel abroad.
Understanding NPM1 and CEBPA Mutations
NPM1 (Nucleophosmin 1) is a gene that encodes a protein involved in ribosome biogenesis and transport. Mutations in the NPM1 gene are found in about one-third of AML cases and are associated with a favorable prognosis. These mutations typically involve a mutation in the NPM1 gene that results in a cytoplasmic localization of the NPM1 protein instead of its normal nuclear localization.
CEBPA (CCAAT/enhancer binding protein alpha) is a gene that encodes a transcription factor involved in myeloid cell differentiation. Mutations in the CEBPA gene are found in about 5-10% of AML cases and are also associated with a favorable prognosis. These mutations typically involve a mutation in one or both copies of the CEBPA gene, resulting in a loss of normal CEBPA function.
The presence of both NPM1 and CEBPA mutations in AML patients has been associated with an even better prognosis compared to the presence of either mutation alone. These patients often respond well to standard chemotherapy treatments and have a higher likelihood of achieving complete remission.
Overall, the detection of NPM1 and CEBPA mutations in AML patients is important for risk stratification and treatment planning.
| Test Name | NPM1and CEBPA Test |
|---|---|
| Components | EDTA Vacutainer (2ml) |
| Price | 2700.0 AED |
| Sample Condition | Bone marrow \/ Peripheral blood (Transport immediately) |
| Report Delivery | 7-8 days |
| Method | Sanger Sequencing |
| Test type | Genetics |
| Doctor | Gynecologist |
| Test Department: | |
| Pre Test Information | NPM1+ CEBPA can be done with a Doctors prescription. Prescription is not applicable for surgery and pregnancy cases or people planing to travel abroad. |
| Test Details |
NPM1 and CEBPA are both genes that are commonly associated with acute myeloid leukemia (AML). NPM1 (Nucleophosmin 1) is a gene that encodes a protein involved in ribosome biogenesis and transport. Mutations in the NPM1 gene are found in about one-third of AML cases and are associated with a favorable prognosis. These mutations typically involve a mutation in the NPM1 gene that results in a cytoplasmic localization of the NPM1 protein instead of its normal nuclear localization. CEBPA (CCAAT/enhancer binding protein alpha) is a gene that encodes a transcription factor involved in myeloid cell differentiation. Mutations in the CEBPA gene are found in about 5-10% of AML cases and are also associated with a favorable prognosis. These mutations typically involve a mutation in one or both copies of the CEBPA gene, resulting in a loss of normal CEBPA function. The presence of both NPM1 and CEBPA mutations in AML patients has been associated with an even better prognosis compared to the presence of either mutation alone. These patients often respond well to standard chemotherapy treatments and have a higher likelihood of achieving complete remission. Overall, the detection of NPM1 and CEBPA mutations in AML patients is important for risk stratification and treatment planning. |
